Renal Cell Carcinoma and Visceral Adipose Index: a new risk parameter

Alper Otunctemur 1, Murat Dursun 1, Kutan Ozer 2, Ozan Horsanali 2, Emin Ozbek 1

1 Department of Urology, Okmeydani, Training and Research Hospital, Istanbul, Turkey; 2 Department of Urology, Ataturk Training and Research Hospital, Izmir, Turkey

INTRODUCTION

Renal cell carcinoma (RCC) accounts for approximately 3% of all adult malignancies, representing the seventh most common cancer in men and the ninth most common cancer in women. Based on current guidelines, surgery remains the only curative treatment option in patients with localized renal cell carcinoma (RCC) (1–3). It is a disease typically presenting in elderly patients with the mean age at diagnosis being around 60 years (4). RCC involving the renal parenchyma accounts for the majority of cases. The predominant subtype of RCC is clear cell type that represents 80% of RCC and is derived from the tubular epithelium. Other types of RCC are papillary (15%), chromophobe (5%), and collecting duct (5, 6).

Several well-established life-style risk factors, such as BMI, hypertension, and smoking, have been identified as potentially predisposing to renal cell carcinoma development (7). Previous studies have reported that diabetes type 2 among women and high BMI and blood pressure among men are independent risk factors for RCC, however, those studies had no data on blood lipids (8, 9). Body fat is known to have biological functions, such as the ability to alter lipid metabolism, modulate numerous adipokines and contribute to
chronic inflammation, among which visceral fat is more metabolically active than peripheral s.c. fat (10). Body fat misdistribution, e.g. visceral obesity, is strongly associated with increased risk of insulin resistance, metabolic syndrome and cardiovascular disease than BMI alone (11). In a previous study, the authors showed that the identification of a routinely applicable indicator for the evaluation of visceral adipose function, with higher sensitivity and specificity than classical parameters [such as waist circumference (WC), BMI, and lipids], could be useful for cardiometabolic risk assessment (12). They calculate a model of adipose distribution (MOAD). To correct MOAD for fat function, TG (mmol/l) and HDL (mmol/L) levels were introduced in the formula. They used the visceral adipose index (VAI) as this formula for cardiometabolic risk assessment.

In our previous study, we reported that patients with metabolic syndrome were found to have statistically significant higher nuclear grade and tumor size (13). Studies show that individuals with BMI 30kg/m² or less, visceral obesity has been shown to be a better marker of health issues related to being overweight, eg cardiovascular disease and metabolic syndrome, than BMI itself. In this context, we thought that we could use the VAI for the assessment of RCC aggressiveness. So, the aim of this study was to evaluate the relationship between tumor size and grade with VAI levels in patients with renal cell carcinoma.

**MATERIAL AND METHODS**

We retrospectively reviewed the records of 310 consecutive patients with RCC who underwent radical nephrectomy at our institution between January 2007 and May 2014. We analyzed the following clinicopathologic variables: age, gender, the presence of hypertension, diabetes, body mass index (BMI), waist circumference, tumor size, histologic subtype, Fuhrman nuclear grade, HDL and triglyceride levels. Plasma fasting glucose, high-density lipoprotein (HDL) cholesterol levels and triglycerides were measured using enzymatic methods with an autoanalyzer. Pathologic staging was performed using the 7th edition of the American Joint Committee on Cancer (AJCC). Histologic subtype was determined according to the 1997 World Health Organization Heidelberg classification and tumor nuclear grading was performed according to the Fuhrman nuclear grading system.

VAI was calculated for males and females separately according to this formula proposed in a previous study (12):

\[
\text{VAI: WC/ [39.68+(1.88 x BMI)] x TG/1.03 x 1.31/ HDL (for male).}
\]

\[
\text{VAI: WC/ [36.58+(1.89 x BMI)] x TG/0.81 x 1.52/ HDL (for female).}
\]

WC: waist circumference, BMI: body mass index, TG: tryglyceride, HDL: high density lipoprotein.

The relationship between tumor size and nuclear grade with VAI levels were evaluated statistically. Local ethics committee approval had been obtained before the commence of the study. Analyses were completed using Chi-square tests and Logistic regression analysis. All statistical tests were two-tailed, and statistical significance was defined as P<0.05. All analysis were conducted using SPSS version 15.0 (SPSS Inc., Chicago, Illinois, USA).

**RESULTS**

Among the 310 total patients analyzed in our study, there were 176 males (56.8%) and 134 females (43.2%). We divided the patients in two groups (tumor size ≥7cm and <7cm). BMI were statistically higher in patients with tumor size ≥7cm than <7cm (p<0.001). Comparison of the men and women with tumor size, the patients with high tumor size had higher TG levels, higher WC and lower HDL-C levels. The difference was statistically significant for all values. Also, we compared the VAI levels between two groups. In men, mean VAI level was 5.26±2.44 in group-1 and 3.58±1.84 in group-2, respectively. In women, mean VAI level was 5.21±2.61 in group-1 and 3.49±1.78 in group-2. VAI levels were statistically higher in men and women with high tumor size (p<0.001). Characteristics of all patients are shown in Table-1.

Also, we compared the VAI levels with Fuhrman grade. We divided the patients into two groups for Fuhrman grade. Fuhrman grade1 and 2 was group-1, Fuhrman grade 3 and 4 was group-2.
BMI were statistically higher in patients with higher Fuhrman grade (p<0.001). Comparison of the men and women with Fuhrman grade, the patients with high Fuhrman grade had higher TG levels, higher WC and lower HDL-C levels. The difference was statistically significant for all values. Also, we compared the VAI levels between two groups. In men, mean VAI level was 5.14±2.32 in group-1 and 3.34±1.56 in group-2, respectively. In women, mean VAI level was 5.16±2.08 in group-1 and 3.09±1.84 in group-2. VAI levels were statistically higher in men and women with high Fuhrman grade (p<0.001) (Table-2). On the other hand, binary logistic regression models showed that VAI is an independently risk factor for renal cell cancer aggressiveness with higher Fuhrman grade and higher tumor size.

**DISCUSSION**

In our study we investigated the correlation between tumor size and grade with visceral adipose index in renal cell carcinoma. Visceral abdominal obesity may have impact on tumor biogenesis since many tumoregenic factors are released from adipose tissue. Furthermore, obesity causes the changes in lipid regulation and results in insulin resistance that may foster cancer development (14). Epidemiological studies performed to date have consistently shown an increased relative risk of RCC with increases in BMI (15). Especially, increased visceral fat was found to be associated with clear-cell RCC. This study showed that, visceral fat area could constitute a primary explanation for the link between obesity and clear cell RCC (16). Conversely, Parker et al. found that patients with an increased BMI were more likely to present with a less aggressive form of RCC (17).

Recent advances have remarkably improved our understanding of the complex role of adipose tissue in carcinogenesis. Adipose tissue can secrete numerous molecules into the bloodstream, which may contribute to a protumorigenic environment. Mortality rates from RCC increase with increasing body mass in a prospective study.

**Table 1 - Characteristics of the patients and comparison to tumor size.**

|                        | Men with tumor size ≥ 7 cm | Men with tumor size < 7 cm | Women with tumor size ≥ 7 cm | Women with tumor size < 7 cm | p value |
|------------------------|----------------------------|----------------------------|-----------------------------|-----------------------------|---------|
| **Age (mean-range)**   | 66.5±12.34                 | 62.8±8.94                  | 68.8±14.21                  | 60.8±9.56                   | 0.52    |
| **BMI (mean±sd)**      | 28.36±2.87                 | 26.84±2.21                 | 29.07±3.05                  | 27.39±3.41                  | <0.001  |
| **Weight (kg, mean±sd)** | 78.64±14.64              | 77.42±16.55                | 74.41±11.48                 | 72.15±13.26                 | 0.41    |
| **Height (meter, mean±sd)** | 1.68±0.42                | 1.69±0.56                  | 1.61±0.84                   | 1.63±0.74                   | 0.95    |
| **WC (cm, mean±sd)**   | 93.77±8.27                 | 91.03±8.51                 | 88.54±7.16                  | 85.16±8.82                  | 0.004   |
| **TG (mg/dL, mean±sd)** | 165.64±71.84              | 129.58±72.21               | 174.46±63.62                | 131.44±78.64                | <0.001  |
| **HDL-C (mg/dL, mean±sd)** | 41.83±7.36               | 47.54±4.28                 | 38.72±7.94                  | 45.41±5.36                  | <0.001  |
| **VAI (mean±sd)**      | 5.26±2.44                  | 3.58±1.84                  | 5.21±2.61                   | 3.49±1.78                   | <0.001  |

**Table 2 - Comparison VAI levels and Fuhrman Grade.**

|                        | Men with Fuhrman Grade 1-2 | Men with Fuhrman Grade 3-4 | Women with Fuhrman Grade 1-2 | Women with Fuhrman Grade 3-4 | p value |
|------------------------|----------------------------|---------------------------|-----------------------------|-----------------------------|---------|
| **VAI (mean±sd)**      | 3.34±1.56                  | 5.14±2.32                 | 3.09±1.84                   | 5.16±2.08                   | <0.001  |
conducted by the American Cancer Society (18). Reasons for these possibly worsened outcomes remain unclear, but may involve the production by adipose tissue of adipokines that may promote cancer growth, and dysregulated angiogenesis (19–21). Indeed, adipose tissue should be considered as an endocrine and paracrine organ that releases cytokine-like polypeptides responsible for widespread biological effects (22). In particular, adipocytes produce insulin-like growth factors, which are known to have cancer-promoting effects on renal cells and multiple angiogenic factors including VEGF and leptin. Leptin exerts direct angiogenic effects (21, 22) and upregulates VEGF mRNA expression. Increased leptin levels have been associated with RCC invasion and progression (23).

WC is a major clinical parameter used for the indirect evaluation of increased visceral fat (23). Nevertheless, WC alone does not help in distinguishing between subcutaneous and visceral fat mass. Because of that, in the previous study authors identified an index that could be used as a surrogate marker of “adipose tissue dysfunction.” VAI was significantly correlated with all metabolic syndrome factors and cardio- and cerebrovascular events (12). The previous study showed that, interestingly, VAI was independently associated with cardiovascular events. These findings might be explained by the fact that VAI includes both physical and metabolic parameters, perhaps indirectly reflecting other nonclassical risk factors, such as altered production of adipocytokines, increased lipolysis and plasma free fatty acids, which are not signified by BMI, WC, TG and HDL separately. Therefore, VAI might be a valuable index of both fat distribution and function. So, in our study we evaluated the relationship between visceral obesity and renal cell cancer aggressiveness, which was previously described.

In a previous study visceral obesity as defined by VAT% was found to be an independent prognostic factor for higher Fuhrman grade in patients with cT1a RCC. In this cohort of 186 patients with cT1a RCC we found that VAT% was an independent prognostic factor for high grade disease after adjusting for clinical characteristics and anatomical features of the tumor (24). Also, a recent study with large series showed that relative visceral obesity as assessed by VAT% was associated with clinicopathological characteristics of localized RCC. A higher VAT% at diagnosis was associated with older age at diagnosis, higher prevalence of diabetes and higher prevalence of former or current smoking status. So, a U-shaped association between VAT% quartiles and the risk of disease recurrence was observed for all patients (25). Like these studies, as an index for evaluation visceral obesity, we found VAI levels were statistically higher in men and women with high Fuhrman grade (p<0.001).

On the other hand, a recent study showed that radiologic measurement of VAT is an independent prognostic factor for Asian patients treated with targeted therapy for advanced renal cell carcinoma. In this study, interestingly the patients with low VAT had double the death rate. The explanation revealed that visceral adipose tissue may be an indicator of nutritional status in patients with advanced RCC (26).

In conclusion, the components of VAI may have effect on tumor carcinogenesis in similar pathways. In our study patients with high VAI levels were found to have statistically significant higher nuclear grade and tumor size. So, the simplicity of WC and BMI measurement and TG and HDL assessment make VAI an easily applicable index for the evaluation of visceral fat dysfunction. VAI can be a useful index for the evaluation and calculation of renal cell cancer aggressiveness. Further studies with more patients are needed to confirm our study.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502-10.
2. Jones J, Libermann TA. Genomics of renal cell cancer: the biology behind and the therapy ahead. Clin Cancer Res. 2007;13:685s-692s.
3. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-4.

4. Patard JJ, Tazi H, Bensalah K, Rodriguez A, Vincendeau S, Rioux-Leclercq N, et al. The changing evolution of renal tumours: a single center experience over a two-decade period. Eur Urol. 2004;45:490-3.

5. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161:147-52.

6. Shanks JH. Pathology of renal cell carcinoma: recent developments. Clin Oncol (R Coll Radiol). 1999;11:263-8.

7. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119-32.

8. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305-11.

9. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305-11.

10. Vohl MC, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res. 2004;12:1217-22.

11. Nedungadi TP, Clegg DJ. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res. 2009;2:321-7.

12. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920-2.

13. Ozbek E, Onuntemur A, Sahin S, Dursun M, Besiroglu H, Koklu I, et al. Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome. Asian Pac J Cancer Prev. 2013;14:7351-4.

14. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11-8.

15. Bergström A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer--a quantitative review. Br J Cancer. 2001;85:984-90.

16. Wang HK, Song XS, Cheng Y, Qu YY, Zhang SL, Dai B, et al. Visceral fat accumulation is associated with different pathological subotypes of renal cell carcinoma (RCC): a multicentre study in China. BJU Int. 2014;114:496-502.

17. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006;68:741-6.

18. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis. 1979;32:563-76.

19. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003;46:1483-8.

20. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005;29:1308-14.

21. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117:2362-8.

22. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol. 2006;28:737-45.

23. Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011;16:71-81.

24. Zhu Y, Wang HK, Zhang HL, Yao XD, Zhang SL, Dai B, et al. Visceral obesity and risk of high grade disease in clinical stage I renal cell carcinoma. J Urol. 2013;189:447-53.

25. Park YH, Lee JK, Kim KM, Kook HR, Lee H, Kim KB, et al. Visceral obesity in predicting oncologic outcomes of localized renal cell carcinoma. J Urol. 2014;192:1043-9.

26. Gu W, Zhu Y, Wang H, Zhang H, Shi G, Liu X, et al. Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series. PLoS One. 2015;10:e0118022.

Correspondence address:
Alper Otunctemur, MD, PhD
Department of Urology, Okmeydani Training and Research Hospital
34384, Sisli, Istanbul, Turkey
Fax: + 90 212 314-5503
E-mail: alperotunctemur@yahoo.com